Resources
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 995
Potential Lenacapavir Supply, 2026-28
Lenacapavir has the potential to reach millions — and the momentum is building. Using the current oral PrEP market as a baseline, this graphic estimates what demand for LEN could look like through 2028 and shows how current donor commitments stack up against that opportunity.
Prevention Option:
Potential Demand for LEN for PrEP
The top 16 PrEP markets, based on 2024 oral PrEP initiations and the possible 2026 injectable market, assuming 60% of new PrEP users choose an injectable, as seen in implementation studies.
Prevention Option:
Source of Lenacapavir for PrEP Supply to Early Adopter Countries
The Global Fund, with support from CIFF, and PEPFAR have jointly committed to reaching up to two million people with injectable lenacapavir for PrEP over three years. Supply of LEN began arriving in countries in late 2025 with service delivery planned to start in early 2026.
Prevention Option:
Overview of Key LEN Dose, Volumes, Timelines and Prices
AVAC developed this summary of key information related to LEN to help drive transparency from all stakeholders and, hopefully, to accelerate the speed, scale and equity in its introduction.
Lenacapavir Implementation Studies
Ongoing and planned implementation studies for the lenacapavir as of March 2026.
Prevention Option:
Opportunities, Controversies & Cruel Ironies
View the slides from AVAC Executive Director Mitchell Warren plenary presentation at SYNChronicity 2026.
Prevention Option:
CROI Cure Reflections Video Series
Produced by PAVE (Pediatric Adolescent Virus Elimination), this weekly series of four videos provides HIV cure-related takeaways from CROI 2026.
Prevention Option:
The Power of bNAbs: A new frontier in HIV cure research
In this video, from the Series of Jojo, viewers are introduced to broadly neutralizing antibodies (bNAbs) and how they might one day be used in finding a functional cure for HIV.
Prevention Option:
EXPrESSIVE Phase III Program Countries of MK-8527
Seventeen countries are hosting sites for the Phase 3 efficacy trials of a monthly PrEP pill, MK-8527, being developed by Merck (also known as MSD outside of the US and Canada). Merck announced the launch of the Phase 3 trials at IAS 2025 in Kigali. MK-8527 was found to be safe and well-tolerated in Phase 2 clinical trials.
Prevention Option:
10 Minutes with JPIDS
Senior Program Manager of Cure Advocacy, Jessica Salzwedel, is featured on the Journal of Pediatric Infectious Disease Society podcast discussing a recent publication on the ethics of pediatric HIV cure research.
Prevention Option:
showing 1-10 of 995